
Contributions
Abstract: EP1391
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - MS symptoms
Background: Walking impairment is an important clinical outcome measure for multiple sclerosis (MS). While the EDSS score is dependent on the maximum walking distance and the use of walking aids, it fails to consider the importance of walking speed. The aim of this study was to assess the effect of walking speed and distance on the activities of daily living (ADLs) and the quality of life of MS patients by using a newly developed Hungarian language ADL questionnaire for MS.
Methods: The study was carried out at the Department of Neurology, University of Szeged. The walking ability of consecutive MS patients at the MS Outpatient Unit of the Department was assessed with the Timed 25-Foot Walk Test (T25FWT) and the time needed to walk 500 meters (500MW), or the maximum possible distance with or without a walking aid was recorded. The validated Hungarian version of the Multiple Sclerosis Quality of Life Instrument (MSQoL-54) was given to the patients. We developed a questionnaire specifically for assessing the impact of MS on walking ability and speed and the effects of walking impairments on ADLs. We translated and adopted to Hungarian some of the questions from previously existing English language instruments. We also wrote additional questions. The resulting questionnaire includes 11 questions rated on a scale with five answer options and 7 questions requiring a 'Yes/No' response. Based on the neurological examination the EDSS scores were determined and clinical and demographic data of the patients were collected. Statistical analysis was performed with the SPSS 22.0 statistical software.
Results: 97 patients were tested. 77% are female, the mean age is 47.6±11.6 years, the mean disease duration is 11.8±6.8 years, the mean EDSS is 3.0±2.0. 90% have relapsing-remitting clinical form. There was a significant negative correlation between MSQoL-54 overall quality of life and T25FWT (p=0.037) and 500MW (p=0.010): patients with higher walking speed had better quality of life. Patients who walk slower had higher ADL scores (having more problems with ADLs): T25FWT (r=0.432, p< 0.001) and 500MW (r=0.501, p< 0.001). Patients who experience more problems with ADLs have worse quality of life: ADL and MSQoL-54 correlation (r=-0.583, p< 0.001).
Conclusions: There is a good correlation between the walking speed and the ADLs of patients with MS. By measuring the walking speed we have a quick method to evaluate the amount of problems they may have in their ADLs.
Disclosure: Dr. Judit Füvesi: nothing to disclose.
Fabian Schmidt: nothing to disclose.
Besma Kirami: nothing to disclose.
Dr. Dániel Sandi: nothing to disclose
Dr. Klaudia Horváth: nothing to disclose.
Dr. Bence Laczó: nothing to disclose
Dr. Krisztina Bencsik: nothing to disclose.
Dr. Tamás Kincses: nothing to disclose.
Dr. Zsanett Fricska-Nagy: nothing to disclose.
Dr. Tamás Biernacki: notjing to disclose.
Prof. Dr. László Vécsei: nothing to disclose.
Abstract: EP1391
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - MS symptoms
Background: Walking impairment is an important clinical outcome measure for multiple sclerosis (MS). While the EDSS score is dependent on the maximum walking distance and the use of walking aids, it fails to consider the importance of walking speed. The aim of this study was to assess the effect of walking speed and distance on the activities of daily living (ADLs) and the quality of life of MS patients by using a newly developed Hungarian language ADL questionnaire for MS.
Methods: The study was carried out at the Department of Neurology, University of Szeged. The walking ability of consecutive MS patients at the MS Outpatient Unit of the Department was assessed with the Timed 25-Foot Walk Test (T25FWT) and the time needed to walk 500 meters (500MW), or the maximum possible distance with or without a walking aid was recorded. The validated Hungarian version of the Multiple Sclerosis Quality of Life Instrument (MSQoL-54) was given to the patients. We developed a questionnaire specifically for assessing the impact of MS on walking ability and speed and the effects of walking impairments on ADLs. We translated and adopted to Hungarian some of the questions from previously existing English language instruments. We also wrote additional questions. The resulting questionnaire includes 11 questions rated on a scale with five answer options and 7 questions requiring a 'Yes/No' response. Based on the neurological examination the EDSS scores were determined and clinical and demographic data of the patients were collected. Statistical analysis was performed with the SPSS 22.0 statistical software.
Results: 97 patients were tested. 77% are female, the mean age is 47.6±11.6 years, the mean disease duration is 11.8±6.8 years, the mean EDSS is 3.0±2.0. 90% have relapsing-remitting clinical form. There was a significant negative correlation between MSQoL-54 overall quality of life and T25FWT (p=0.037) and 500MW (p=0.010): patients with higher walking speed had better quality of life. Patients who walk slower had higher ADL scores (having more problems with ADLs): T25FWT (r=0.432, p< 0.001) and 500MW (r=0.501, p< 0.001). Patients who experience more problems with ADLs have worse quality of life: ADL and MSQoL-54 correlation (r=-0.583, p< 0.001).
Conclusions: There is a good correlation between the walking speed and the ADLs of patients with MS. By measuring the walking speed we have a quick method to evaluate the amount of problems they may have in their ADLs.
Disclosure: Dr. Judit Füvesi: nothing to disclose.
Fabian Schmidt: nothing to disclose.
Besma Kirami: nothing to disclose.
Dr. Dániel Sandi: nothing to disclose
Dr. Klaudia Horváth: nothing to disclose.
Dr. Bence Laczó: nothing to disclose
Dr. Krisztina Bencsik: nothing to disclose.
Dr. Tamás Kincses: nothing to disclose.
Dr. Zsanett Fricska-Nagy: nothing to disclose.
Dr. Tamás Biernacki: notjing to disclose.
Prof. Dr. László Vécsei: nothing to disclose.